Suppr超能文献

木脂素类似物作为新型血小板活化因子受体拮抗剂的化学和生化特性

Chemical and biochemical characterization of lignan analogs as novel PAF receptor antagonists.

作者信息

Shen T Y

机构信息

Department of Chemistry, University of Virginia, Charlottesville 22901.

出版信息

Lipids. 1991 Dec;26(12):1154-6. doi: 10.1007/BF02536521.

Abstract

Various derivatives and isosteres of neolignans of the 2,5-diaryl tetrahydrofuran type have been synthesized as antagonists of platelet-activating factor (PAF). A detailed analysis of their structure-activity relationship (SAR) has revealed a clear preference for an asymmetrical molecular configuration with a high degree of stereo and chiral specificity associated with greater potency. The trans-2S,5S enantiomers are generally 10-200 times more potent in vitro than their corresponding cis or trans-2R,5R isomers. A similar stereochemical preference is indicated by the recently reported PAF antagonist MK-287 which has undergone clinical evaluation. An azido derivative L-662,025 has been characterized as a photolabile irreversible antagonist of PAF for the investigation of solubilized and partially purified PAF binding proteins from cell membranes. The biological justification for concomitant inhibition of both PAF receptor and 5-lipoxygenase in inflammation is well recognized. The feasibility of developing such dual-functional agents has been demonstrated by a group of dithiolane analogs of neolignans and several derivatives of futoenone.

摘要

已合成了多种2,5 - 二芳基四氢呋喃型新木脂素的衍生物和生物电子等排体,作为血小板活化因子(PAF)的拮抗剂。对其构效关系(SAR)的详细分析表明,具有高度立体和手性特异性且与更高活性相关的不对称分子构型具有明显优势。反式 - 2S,5S对映体在体外的活性通常比其相应的顺式或反式 - 2R,5R异构体高10 - 200倍。最近报道的已进行临床评估的PAF拮抗剂MK - 287也表明了类似的立体化学偏好。叠氮基衍生物L - 662,025已被表征为PAF的光不稳定不可逆拮抗剂,用于研究从细胞膜中溶解和部分纯化的PAF结合蛋白。同时抑制PAF受体和5 - 脂氧合酶在炎症中的生物学依据已得到充分认可。一组新木脂素的二硫杂环戊烷类似物和呋豆酮的几种衍生物已证明开发这种双功能药物的可行性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验